Contents
- IWJ-75Frozen · 75mg · 3mL
- IIWJ-95Lyophilised · 95mg
- IIIWJ-150Frozen · 150mg · 1mL
- IVWJ-300Frozen · 300mg · 2mL
Wharton's jelly is the connective tissue matrix of the human umbilical cord — a structurally rich, hydrated extracellular environment present at the peak of biological development. It is not a signalling product. It is the architecture within which signalling occurs.
Wharton's jelly formulations are classified by total tissue content, concentration and format — not by potency or hierarchy. Two formulations may share a concentration and differ only in volume. Each configuration serves a distinct structural context. Selection is determined by the tissue environment being addressed.
WJ-75 is configured for broad matrix distribution across larger surface-level tissue environments. Its lower concentration across a greater volume makes it the appropriate selection when extracellular matrix presence is desired across an expanded area rather than concentrated at a single site.
Provided as pure Wharton's jelly in frozen format — not lyophilised, not combined with exosomes or conditioned media, and not chemically modified. The matrix is preserved as close to its native state as possible.
WJ-95 is the only lyophilised formulation within the RENOVÓ Wharton's jelly series — a format that allows controlled reconstitution prior to placement, enabling more precise matrix delivery in environments where concentrated extracellular matrix presence is desired in a smaller area. Because it is supplied as a powder, its concentration is set by the practitioner at reconstitution rather than fixed at fill.
As the entry formulation of the series, WJ-95 provides a stable, transportable option for contexts where the flexibility of lyophilisation is clinically advantageous. Its matrix is reconstituted before placement; RENOVÓ does not claim that reconstitution restores the native state of the tissue.
WJ-150 provides double the matrix content of WJ-75 within a significantly smaller delivery volume — 150 mg in 1 mL, a concentration of 150 mg/mL. It is the appropriate selection when concentrated extracellular matrix presence is required in a targeted area rather than distributed across a broader surface.
Its frozen format preserves the native matrix structure and hydration characteristics of Wharton's jelly without the reconstitution step required for WJ-95. Pure matrix, concentrated, in a format that maintains the tissue's inherent biological architecture.
WJ-300 is the largest-volume formulation of the RENOVÓ Wharton's jelly series — 300 mg of tissue in 2 mL, a concentration of 150 mg/mL identical to WJ-150. What distinguishes it is not density but reach: double the total tissue content across double the volume, for environments where a greater extent of matrix presence is appropriate.
Like all Wharton's jelly formulations within the RENOVÓ platform, WJ-300 contains pure tissue — not lyophilised, not combined with other biological categories, and not chemically modified. Its classification is based entirely on total tissue content and volume rather than concentration, signalling density or potency.
| Product | Format | Tissue Content | Volume | Density Configuration | Primary Context |
|---|---|---|---|---|---|
I WJ-75Broad Distribution |
Frozen | 75 mg | 3 mL | 25 mg/mL · broad area | SurfaceBroad Coverage |
II WJ-95Reconstitutable Matrix |
Lyophilised | 95 mg | As supplied | Set at reconstitution · small area | ConcentratedFlexible Delivery |
III WJ-150High Density Matrix |
Frozen | 150 mg | 1 mL | 150 mg/mL · targeted | TargetedMusculoskeletal |
IV WJ-300Maximum Volume |
Frozen | 300 mg | 2 mL | 150 mg/mL · expanded volume | ExpandedAdvanced Clinical |
It is the environment in which signalling becomes possible.